What drugs does THERATECHNOLOGIES make?

THERATECHNOLOGIES has 3 FDA-approved drugs including TROGARZO, Egrifta WR.

What therapeutic areas does THERATECHNOLOGIES focus on?

THERATECHNOLOGIES focuses primarily on Infectious Disease and Immunology and 1 other therapeutic areas.

Data updated: Jun 28, 2026

THERATECHNOLOGIES

Biotech

Infectious Disease Immunology Respiratory

THERATECHNOLOGIES is a biotechnology company focused on Infectious Disease, Immunology, Respiratory. Key products include Egrifta WR.

2010

Since

Drugs

Trials

New Drugs (2yr)

Modality:

2 Biologics

FDA Novel Drug Designations

(2018)

1 Novel 1 First-in-Class 1 Orphan 1 Breakthrough 1 Priority Review 1 Fast Track

See 1 novel approval →

2018 TROGARZO (IBALIZUMAB-UIYK) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track

THERATECHNOLOGIES's Key Drugs

THERATECHNOLOGIES's core commercial portfolio centers on TROGARZO, Egrifta WR, spanning Infectious Disease and Immunology — its most strategically important drugs approved in the last 15 years.

TROGARZO

Infectious Disease

Human Immunodeficiency Virus Infection

Approved 2018

Egrifta WR

Approved 2025

THERATECHNOLOGIES's Recent FDA Approvals

THERATECHNOLOGIES secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

Egrifta WR BLA

2025-03-24

tesamorelin

1 INDICATIONS AND USAGE EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA WR has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA WR. EGRIFTA WR is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. ( 1 ) Limitations of use: Long-term cardiovascular safety of EGRIFTA WR has not been established. ( 1 ) Not indicated for weight loss management. ( 1 ) There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA WR. ( 1 )

THERATECHNOLOGIES's Therapeutic Areas

THERATECHNOLOGIES's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Immunology, across 2 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 44%

1 drugs Phase 1: 2

Immunology 33%

1 drugs

Respiratory 11%

0 drugs Phase 2: 1

Oncology 6%

0 drugs Phase 1: 1

Metabolic 6%

0 drugs Phase 1: 1

THERATECHNOLOGIES's Top Competitors

THERATECHNOLOGIES's closest competitors by therapeutic-area and drug-target overlap include GSK, Merck, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

GSK big-pharma

Respiratory, Infectious Disease, Oncology, Immunology, Metabolic

Merck big-pharma

Oncology, Infectious Disease, Metabolic, Respiratory

Johnson & Johnson big-pharma

Oncology, Immunology, Infectious Disease, Metabolic

Sanofi big-pharma

Metabolic, Oncology, Infectious Disease, Immunology

AstraZeneca big-pharma

Oncology, Respiratory, Metabolic, Immunology